Academic and Community Cancer Research United
Welcome,         Profile    Billing    Logout  
 48 Trials 
21 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Loprinzi, Charles L
NCT05791474: ATI-2231 in Advanced Solid Tumor Malignancies

Withdrawn
1
36
NA
ATI-2231
Washington University School of Medicine, Aclaris Therapeutics, Inc.
Advanced Solid Tumor, Advanced Solid Tumor Malignancies
06/25
06/25
Stinchcombe, Thomas
SGNTUC-019, NCT04579380: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
Cheson, Bruce D
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
02/25
08/28
NCT04545333: The clonoSEQ® Watch Registry

Terminated
N/A
465
US
clonoSEQ Assay
Adaptive Biotechnologies
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
10/23
10/23
realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting
N/A
100
US
Tafasitamab
Incyte Corporation, Iqvia Pty Ltd
Diffuse Large B-cell Lymphoma
10/25
08/26
Ho, Alan
NCT02749903: Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Active, not recruiting
2
46
US
enzalutamide
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Astellas Pharma US, Inc.
Salivary Cancer
02/19
07/22
NCT02098538: Regorafenib in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Completed
2
38
US
Regorafenib
Memorial Sloan Kettering Cancer Center, Bayer
Adenoid Cystic Carcinoma
11/24
11/24
NCT04209660: Lenvatinib and Pembrolizumab in People with Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Active, not recruiting
2
64
US
Lenvatinib, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Eisai Inc.
Adenoid Cystic Carcinoma, Salivary Gland Cancer
12/25
12/25
NCT04620187: Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Recruiting
2
55
US
Ado-trastuzumab (T) emtansine (T-DM1), Kadcyla, Standard of Care Radiotherapy, Radiation, Standard of Care Chemotherapy, Cisplatin, carboplatin
Dana-Farber Cancer Institute, Genentech, Inc.
Salivary Gland Cancer, HER2 Gene Mutation
02/25
02/26
NCT02780310: Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma

Checkmark In patients with progressive, recurrent or metastatic adenoid cystic carcinoma
Apr 2019 - Apr 2019: In patients with progressive, recurrent or metastatic adenoid cystic carcinoma
Active, not recruiting
2
33
US
Lenvatinib
Memorial Sloan Kettering Cancer Center, Eisai Inc.
Adenoid Cystic Carcinoma
05/25
05/25
NCT03172624: Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Active, not recruiting
2
64
US
Nivolumab, Ipilimumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb
Salivary Gland Cancer
05/25
05/25
NCT06007924: A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Recruiting
2
30
US
Avutometinib, Defactinib
Memorial Sloan Kettering Cancer Center, Verastem, Inc.
Thyroid Cancer
08/27
08/27
KURRENT-HN, NCT04997902: Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Recruiting
1/2
40
US
Tipifarnib, Alpelisib, BYL719
Kura Oncology, Inc.
HNSCC
09/24
09/24
NCT03215095: RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Active, not recruiting
1
11
US
Durvalumab (Medi4736), Radioiodine (RAI)
Memorial Sloan Kettering Cancer Center, AstraZeneca, MedImmune LLC
Thyroid Cancer
02/23
07/25
AVENTIL, NCT05222932: Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

Recruiting
1
15
Europe, US
TILT-123, TNFalpha and IL-2 coding oncolytic adenovirus TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2, Avelumab, anti-PD-L1 monoclonal antibody
TILT Biotherapeutics Ltd.
Melanoma, Head and Neck Squamous Cell Carcinoma
12/24
12/26
REM-422-101, NCT06118086: Study of REM-422 in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma

Recruiting
1
65
US
REM-422
Remix Therapeutics
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
06/25
06/26
NCT02145143: Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers with the BRAF Inhibitor Vemurafenib: a Pilot Study

Completed
N/A
12
US
Vemurafenib, RO5185426,, PLX4032, RG7204, serial 124I PET/CT, thyrotropin alpha, Thyrogen, Genzyme
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Thyroid Carcinoma
11/24
11/24
Nowakowski, Grzegorz S
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
12/24
04/25
Bergsland, Emily
NCT05746208: Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Recruiting
2
29
US
Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Hyperpolarized 13C-Pyruvate, HP 13C
University of California, San Francisco, Merck Sharp & Dohme LLC
Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
07/27
10/27

Download Options